Active versus passive pluralism: A changing style of civil religion
In: Peace research abstracts journal, Band 44, Heft 6, S. 133
ISSN: 0031-3599
7 Ergebnisse
Sortierung:
In: Peace research abstracts journal, Band 44, Heft 6, S. 133
ISSN: 0031-3599
In: Israel affairs, Band 5, Heft 2-3, S. 200-225
ISSN: 1353-7121
In: The annals of the American Academy of Political and Social Science, Band 558, S. 144-162
ISSN: 0002-7162
Explores the relationship between sacrality & sovereignty, ie, between symbolic & material realities, in Jerusalem's (Israel) politics from the Six Day War of 1967 to the present & as Jerusalem moves toward the millennium. Efforts to separate the city's sacred places from political solutions are described, with attention to how this affects religious traditions & their communities in the city. Also addressed are the growing symbolic importance of Jerusalem for US evangelical Christians & how the city functions as a ritual theater for Israeli & Palestinian politics. Finally, it is discussed how the city is doubly cleaved between communities at the level of politics & in each community around the relationship between the political order & the religious order, especially since the signing of the Oslo accords & the defeat in 1993 of Jerusalem's longtime liberal mayor, Teddy Kollek, & his replacement by Center-Right Likud mayor Ehud Olmert. 17 References. Adapted from the source document.
In: Resch , S , Korenromp , E , Stover , J , Blakley , M , Krubiner , C , Thorien , K , Hecht , R & Atun , R 2011 , ' Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries ' , PLoS One (print) , vol. 6 , no. 10 . https://doi.org/10.1371/journal.pone.0025310
Since the early 2000s, aid organizations and developing country governments have invested heavily in AIDS treatment. By 2010, more than five million people began receiving antiretroviral therapy (ART) - yet each year, 2.7 million people are becoming newly infected and another two million are dying without ever having received treatment. As the need for treatment grows without commensurate increase in the amount of available resources, it is critical to assess the health and economic gains being realized from increasingly large investments in ART. This study estimates total program costs and compares them with selected economic benefits of ART, for the current cohort of patients whose treatment is cofinanced by the Global Fund to Fight AIDS, Tuberculosis and Malaria. At end 2011, 3.5 million patients in low and middle income countries will be receiving ART through treatment programs cofinanced by the Global Fund. Using 2009 ART prices and program costs, we estimate that the discounted resource needs required for maintaining this cohort are $14.2 billion for the period 2011-2020. This investment is expected to save 18.5 million life-years and return $12 to $34 billion through increased labor productivity, averted orphan care, and deferred medical treatment for opportunistic infections and end-of-life care. Under alternative assumptions regarding the labor productivity effects of HIV infection, AIDS disease, and ART, the monetary benefits range from 81 percent to 287 percent of program costs over the same period. These results suggest that, in addition to the large health gains generated, the economic benefits of treatment will substantially offset, and likely exceed, program costs within 10 years of investment.
BASE
Since the early 2000s, aid organizations and developing country governments have invested heavily in AIDS treatment. By 2010, more than five million people began receiving antiretroviral therapy (ART) - yet each year, 2.7 million people are becoming newly infected and another two million are dying without ever having received treatment. As the need for treatment grows without commensurate increase in the amount of available resources, it is critical to assess the health and economic gains being realized from increasingly large investments in ART. This study estimates total program costs and compares them with selected economic benefits of ART, for the current cohort of patients whose treatment is cofinanced by the Global Fund to Fight AIDS, Tuberculosis and Malaria. At end 2011, 3.5 million patients in low and middle income countries will be receiving ART through treatment programs cofinanced by the Global Fund. Using 2009 ART prices and program costs, we estimate that the discounted resource needs required for maintaining this cohort are $14.2 billion for the period 2011-2020. This investment is expected to save 18.5 million life-years and return $12 to $34 billion through increased labor productivity, averted orphan care, and deferred medical treatment for opportunistic infections and end-of-life care. Under alternative assumptions regarding the labor productivity effects of HIV infection, AIDS disease, and ART, the monetary benefits range from 81 percent to 287 percent of program costs over the same period. These results suggest that, in addition to the large health gains generated, the economic benefits of treatment will substantially offset, and likely exceed, program costs within 10 years of investment.
BASE
In: http://hdl.handle.net/11427/19355
It is axiomatic that the global fight against HIV/AIDS cannot be won without a decisive victory in South Africa, home to 20 percent of all people living with HIV/AIDS. So how is South Africa doing? And what is the likelihood it will meet the demand for essential prevention and treatment interventions by 2015? On Jan. 21 in Cape Town, Council on Foreign Relations Global Health Fellow Dr. Peter Navario convened a meeting of South Africa's foremost HIV/AIDS thinkers, policy-makers and practitioners to discuss the state of prevention and treatment at the epicenter of the pandemic. In this article, the experts weigh in on program gaps, the major challenges to achieving universal coverage of essential prevention and treatment interventions, and what it will take to surmount these challenges.
BASE
Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have a significant impact on these epidemics and save lives in a cost-effective, affordable manner. In this context, our team used an investment case approach to develop a national hepatitis action plan for South Africa, grounded in a process of intensive engagement of local stakeholders. Costs were estimated for each activity using an ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed models calibrated to South Africa's demographic and epidemic profile. The Action Plan is estimated to require ZAR3.8 billion (US$294 million) over 2017-2021, about 0.5% of projected government health spending. Treatment scale-up over the initial 5-year period would avert 13 000 HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at $3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests that the proposed scale-up can be accommodated within South Africa's fiscal space and represents good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to assess the costs and relative priority of scaling up HBV/HCV services.
BASE